THR 100
Alternative Names: Recombinant staphylokinase variant - Bharat Biotech; Sak42D; THR100Latest Information Update: 24 Oct 2021
At a glance
- Originator University of Leuven
- Developer Bharat Biotech
- Class Metalloendopeptidases; Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
- Mechanism of Action Plasminogen activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Myocardial infarction
Most Recent Events
- 10 Sep 2018 Thrombogenics is now called Oxurion
- 31 Aug 2011 Bharat Biotech completes a phase III trial in Myocardial infarction in India (NCT01305226)
- 04 Feb 2010 Phase-III clinical trials in Myocardial infarction in India (IV)